Which calcium channel blocker for ischaemic heart disease?
Related Experiment Videos
Insights
Calcium channel blockers, used since the 1960s, are reviewed for treating ischemic heart disease. Research evaluates their impact on atheroma progression and specific cardiac events like myocardial infarction and unstable angina.
Area of Science:
- Cardiology and Pharmacology
- Focus on cardiovascular disease treatment
Background:
- Calcium channel blockers have been clinically available since the early 1960s.
- Extensive research has explored their therapeutic applications in cardiovascular medicine.
Purpose of the Study:
- To review the pharmacology of calcium channel blockers.
- To evaluate their clinical utility in ischemic heart disease management.
- To examine effects on atheroma progression and specific clinical scenarios.
Main Methods:
- Comprehensive review of existing pharmacological data.
- Analysis of major clinical trials involving calcium channel blockers.
- Examination of studies focusing on atheroma progression.
- Assessment of roles in post-myocardial infarction and unstable angina settings.
Main Results:
- The review synthesizes pharmacological properties and clinical trial outcomes.
- Evidence regarding the impact on atheroma progression is analyzed.
- The efficacy in specific patient groups (post-MI, unstable angina) is discussed.
Conclusions:
- Calcium channel blockers represent a significant class of drugs in ischemic heart disease.
- Their role in managing atheroma progression and acute coronary syndromes warrants continued clinical consideration.
Abstract:
Calcium channel blockers have been available since the early 1960s. Extensive research has been undertaken to evaluate their usefulness in the treatment of patients with ischaemic heart disease. We have reviewed the pharmacology of these drugs and the major clinical trials. In particular, we have examined the effect of calcium channel blockers on the progression of atheroma, and their role in the following clinical settings: following myocardial infarction, following non-Q-wave myocardial infarction, and in unstable angina.